Diamedica Therapeutics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Dialectic Life Sciences SPV LLC and related entities filed an amended Schedule 13G, reporting John Fichthorn's beneficial ownership of 0.3% in DiaMedica Therapeutics Inc.
NASDAQ
Trill AB and Jan Stahlberg have reported a 16.9% beneficial ownership stake in DiaMedica Therapeutics Inc., holding 8,825,742 common shares.
NASDAQ
Richard Jacinto II has increased his beneficial ownership in DiaMedica Therapeutics Inc. to 9.6% of outstanding Voting Common Shares.
NASDAQ
Leon G. Cooperman and his foundation have reported a 6.3% beneficial ownership stake in DiaMedica Therapeutics Inc., totaling 3,269,761 common shares.
NASDAQ
Trill AB and Jan Stahlberg have reported a combined beneficial ownership of 15.02% of DiaMedica Therapeutics Inc. common shares.
NASDAQ
Veteran investor Leon Cooperman has revealed a 6% passive ownership stake in DiaMedica Therapeutics Inc., holding over 3.1 million common shares.
NASDAQ
Trill AB and its beneficial owner Jan Stahlberg have reported a 13.14% beneficial ownership stake in DiaMedica Therapeutics Inc., holding 6,764,465 common shares.
NASDAQ
TomEnterprise AB, TomEnterprise Private AB, and Thomas von Koch have collectively reported beneficial ownership of 16.28% of DiaMedica Therapeutics Inc.'s common shares.